Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.19
HOLX's Cash-to-Debt is ranked lower than
88% of the 172 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. HOLX: 0.19 )
Ranked among companies with meaningful Cash-to-Debt only.
HOLX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04  Med: 0.6 Max: No Debt
Current: 0.19
Equity-to-Asset 0.30
HOLX's Equity-to-Asset is ranked lower than
86% of the 168 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. HOLX: 0.30 )
Ranked among companies with meaningful Equity-to-Asset only.
HOLX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.22  Med: 0.6 Max: 0.88
Current: 0.3
0.22
0.88
Interest Coverage 3.63
HOLX's Interest Coverage is ranked lower than
89% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 39.88 vs. HOLX: 3.63 )
Ranked among companies with meaningful Interest Coverage only.
HOLX' s Interest Coverage Range Over the Past 10 Years
Min: 0.55  Med: 2.21 Max: 71.1
Current: 3.63
0.55
71.1
Piotroski F-Score: 9
Altman Z-Score: 1.63
Beneish M-Score: -2.84
WACC vs ROIC
6.23%
9.02%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 19.79
HOLX's Operating Margin % is ranked higher than
83% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.65 vs. HOLX: 19.79 )
Ranked among companies with meaningful Operating Margin % only.
HOLX' s Operating Margin % Range Over the Past 10 Years
Min: -123.18  Med: 8.37 Max: 20.93
Current: 19.79
-123.18
20.93
Net Margin % 11.57
HOLX's Net Margin % is ranked higher than
78% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.23 vs. HOLX: 11.57 )
Ranked among companies with meaningful Net Margin % only.
HOLX' s Net Margin % Range Over the Past 10 Years
Min: -135.4  Med: -1.5 Max: 12.81
Current: 11.57
-135.4
12.81
ROE % 15.64
HOLX's ROE % is ranked higher than
80% of the 164 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.98 vs. HOLX: 15.64 )
Ranked among companies with meaningful ROE % only.
HOLX' s ROE % Range Over the Past 10 Years
Min: -60.17  Med: -0.73 Max: 15.67
Current: 15.64
-60.17
15.67
ROA % 4.50
HOLX's ROA % is ranked higher than
60% of the 173 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.97 vs. HOLX: 4.50 )
Ranked among companies with meaningful ROA % only.
HOLX' s ROA % Range Over the Past 10 Years
Min: -32.08  Med: -0.35 Max: 9.84
Current: 4.5
-32.08
9.84
ROC (Joel Greenblatt) % 68.34
HOLX's ROC (Joel Greenblatt) % is ranked higher than
90% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.87 vs. HOLX: 68.34 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
HOLX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -369.68  Med: 25.23 Max: 90.76
Current: 68.34
-369.68
90.76
3-Year Revenue Growth Rate 2.20
HOLX's 3-Year Revenue Growth Rate is ranked lower than
59% of the 147 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.20 vs. HOLX: 2.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
HOLX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -7.7  Med: 10.3 Max: 35.9
Current: 2.2
-7.7
35.9
GuruFocus has detected 3 Warning Signs with Hologic Inc $HOLX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» HOLX's 10-Y Financials

Financials (Next Earnings Date: 2017-05-01 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

HOLX Guru Trades in Q1 2016

Paul Tudor Jones 45,242 sh (New)
Ray Dalio 52,900 sh (New)
Ken Fisher 47,620 sh (+0.04%)
Vanguard Health Care Fund 5,802,700 sh (unchged)
Murray Stahl Sold Out
Carl Icahn Sold Out
Kahn Brothers 1,326,484 sh (-1.76%)
RS Investment Management 924,598 sh (-19.09%)
Pioneer Investments 112,646 sh (-23.46%)
Jim Simons 1,267,918 sh (-23.95%)
Steven Cohen 557,200 sh (-44.19%)
Joel Greenblatt 19,794 sh (-94.86%)
» More
Q2 2016

HOLX Guru Trades in Q2 2016

Robert Olstein 187,000 sh (New)
Leon Cooperman 100,000 sh (New)
Paul Tudor Jones 1,310,684 sh (+2797.05%)
Joel Greenblatt 31,837 sh (+60.84%)
Steven Cohen 715,700 sh (+28.45%)
Vanguard Health Care Fund 7,306,800 sh (+25.92%)
Steven Cohen 55,500 sh (unchged)
Ray Dalio Sold Out
RS Investment Management Sold Out
Jim Simons Sold Out
Kahn Brothers 1,276,984 sh (-3.73%)
Ken Fisher 37,600 sh (-21.04%)
Pioneer Investments 58,312 sh (-48.23%)
» More
Q3 2016

HOLX Guru Trades in Q3 2016

Jim Simons 590,018 sh (New)
George Soros 7,236 sh (New)
Joel Greenblatt 103,903 sh (+226.36%)
Steven Cohen 1,315,600 sh (+83.82%)
Pioneer Investments 85,816 sh (+47.17%)
Robert Olstein 187,000 sh (unchged)
Ken Fisher Sold Out
Leon Cooperman Sold Out
Kahn Brothers 1,234,514 sh (-3.33%)
Vanguard Health Care Fund 6,896,300 sh (-5.62%)
Paul Tudor Jones 1,200,000 sh (-8.44%)
» More
Q4 2016

HOLX Guru Trades in Q4 2016

Jim Simons 1,463,618 sh (+148.06%)
Pioneer Investments 173,374 sh (+102.03%)
George Soros Sold Out
Joel Greenblatt Sold Out
Robert Olstein 184,000 sh (-1.60%)
Kahn Brothers 1,197,404 sh (-3.01%)
Steven Cohen 1,142,100 sh (-13.19%)
Vanguard Health Care Fund 3,538,200 sh (-48.69%)
Paul Tudor Jones 500,000 sh (-58.33%)
» More
» Details

Insider Trades

Latest Guru Trades with HOLX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 334517    SIC: 3844
Compare:OTCPK:TRUMF, NYSE:WAT, NYSE:MTD, OTCPK:OCPNY, NYSE:RMD, NYSE:COO, NAS:XRAY, OTCPK:SAUHY, OTCPK:CLPBY, NYSE:WST, NYSE:STE, NYSE:BCR, NYSE:HRC, OTCPK:GNGBY, NYSE:CMD, NAS:ICUI, OTCPK:ANSLY, NAS:PODD, NYSE:HAE, OTCPK:TOPCF » details
Traded in other countries:HO1.Germany,
Hologic Inc is a developer, manufacturer and supplier of medical imaging systems and diagnostic and surgical products serving the healthcare needs of women.

Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (47% of sales), breast health (37%), surgical (12%), and skeletal health (4%). While the company traditionally focused on breast health, the recent acquisition of Gen-Probe puts a much greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (74%), followed by Europe (12%) and Asia (8%). Hologic is headquartered in Bedford, Massachusetts.

Top Ranked Articles about Hologic Inc

Carl Icahn Continues to Reduce Position in Hologic Guru slashes more than 3 million shares from his portfolio
Guru Carl Icahn (Trades, Portfolio) reduced his position in Hologic Inc. (NASDAQ:HOLX), slashing 3,346,767 shares from his portfolio Monday. Read more...

Ratios

vs
industry
vs
history
PE Ratio 36.44
HOLX's PE Ratio is ranked lower than
63% of the 139 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.61 vs. HOLX: 36.44 )
Ranked among companies with meaningful PE Ratio only.
HOLX' s PE Ratio Range Over the Past 10 Years
Min: 25.41  Med: 55.98 Max: 472.67
Current: 36.44
25.41
472.67
Forward PE Ratio 22.03
HOLX's Forward PE Ratio is ranked higher than
62% of the 40 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.75 vs. HOLX: 22.03 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 36.44
HOLX's PE Ratio without NRI is ranked lower than
62% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.85 vs. HOLX: 36.44 )
Ranked among companies with meaningful PE Ratio without NRI only.
HOLX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 25.41  Med: 55.3 Max: 472.67
Current: 36.44
25.41
472.67
Price-to-Owner-Earnings 20.55
HOLX's Price-to-Owner-Earnings is ranked higher than
71% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.68 vs. HOLX: 20.55 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
HOLX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 10.77  Med: 24.75 Max: 311.63
Current: 20.55
10.77
311.63
PB Ratio 5.32
HOLX's PB Ratio is ranked lower than
71% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.38 vs. HOLX: 5.32 )
Ranked among companies with meaningful PB Ratio only.
HOLX' s PB Ratio Range Over the Past 10 Years
Min: 0.59  Med: 2 Max: 7.98
Current: 5.32
0.59
7.98
PS Ratio 4.22
HOLX's PS Ratio is ranked lower than
62% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.85 vs. HOLX: 4.22 )
Ranked among companies with meaningful PS Ratio only.
HOLX' s PS Ratio Range Over the Past 10 Years
Min: 1.45  Med: 2.9 Max: 5.97
Current: 4.22
1.45
5.97
Price-to-Free-Cash-Flow 17.79
HOLX's Price-to-Free-Cash-Flow is ranked higher than
78% of the 76 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.12 vs. HOLX: 17.79 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
HOLX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 6.45  Med: 15.09 Max: 514.17
Current: 17.79
6.45
514.17
Price-to-Operating-Cash-Flow 15.46
HOLX's Price-to-Operating-Cash-Flow is ranked higher than
61% of the 97 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.55 vs. HOLX: 15.46 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
HOLX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.45  Med: 13.06 Max: 140.85
Current: 15.46
5.45
140.85
EV-to-EBIT 25.43
HOLX's EV-to-EBIT is ranked lower than
57% of the 153 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.23 vs. HOLX: 25.43 )
Ranked among companies with meaningful EV-to-EBIT only.
HOLX' s EV-to-EBIT Range Over the Past 10 Years
Min: -137.4  Med: 26.85 Max: 153.7
Current: 25.43
-137.4
153.7
EV-to-EBITDA 14.04
HOLX's EV-to-EBITDA is ranked higher than
65% of the 165 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.75 vs. HOLX: 14.04 )
Ranked among companies with meaningful EV-to-EBITDA only.
HOLX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -344.2  Med: 13.2 Max: 100.6
Current: 14.04
-344.2
100.6
Current Ratio 1.81
HOLX's Current Ratio is ranked lower than
68% of the 168 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.40 vs. HOLX: 1.81 )
Ranked among companies with meaningful Current Ratio only.
HOLX' s Current Ratio Range Over the Past 10 Years
Min: 1.07  Med: 2.64 Max: 7.31
Current: 1.81
1.07
7.31
Quick Ratio 1.61
HOLX's Quick Ratio is ranked lower than
52% of the 168 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.64 vs. HOLX: 1.61 )
Ranked among companies with meaningful Quick Ratio only.
HOLX' s Quick Ratio Range Over the Past 10 Years
Min: 0.85  Med: 2.05 Max: 6.57
Current: 1.61
0.85
6.57
Days Inventory 78.80
HOLX's Days Inventory is ranked higher than
77% of the 158 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 126.59 vs. HOLX: 78.80 )
Ranked among companies with meaningful Days Inventory only.
HOLX' s Days Inventory Range Over the Past 10 Years
Min: 65.34  Med: 88.04 Max: 108.2
Current: 78.8
65.34
108.2
Days Sales Outstanding 53.36
HOLX's Days Sales Outstanding is ranked higher than
68% of the 142 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.07 vs. HOLX: 53.36 )
Ranked among companies with meaningful Days Sales Outstanding only.
HOLX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 53.36  Med: 60.73 Max: 75.51
Current: 53.36
53.36
75.51
Days Payable 39.46
HOLX's Days Payable is ranked lower than
64% of the 129 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 49.88 vs. HOLX: 39.46 )
Ranked among companies with meaningful Days Payable only.
HOLX' s Days Payable Range Over the Past 10 Years
Min: 21.81  Med: 27.28 Max: 45.11
Current: 39.46
21.81
45.11

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.70
HOLX's 3-Year Average Share Buyback Ratio is ranked higher than
67% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.70 vs. HOLX: -0.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
HOLX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -42.6  Med: -6.1 Max: -0.7
Current: -0.7
-42.6
-0.7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.79
HOLX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
61% of the 90 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.04 vs. HOLX: 1.79 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
HOLX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.41  Med: 1.49 Max: 12.14
Current: 1.79
0.41
12.14
Price-to-Median-PS-Value 1.46
HOLX's Price-to-Median-PS-Value is ranked lower than
71% of the 165 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.14 vs. HOLX: 1.46 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
HOLX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.15  Med: 0.88 Max: 2.59
Current: 1.46
0.15
2.59
Earnings Yield (Greenblatt) % 3.93
HOLX's Earnings Yield (Greenblatt) % is ranked higher than
63% of the 230 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.20 vs. HOLX: 3.93 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
HOLX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.7  Med: 2.9 Max: 7.2
Current: 3.93
0.7
7.2
Forward Rate of Return (Yacktman) % 26.49
HOLX's Forward Rate of Return (Yacktman) % is ranked higher than
84% of the 90 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.56 vs. HOLX: 26.49 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
HOLX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 0.4  Med: 6.9 Max: 72.6
Current: 26.49
0.4
72.6

More Statistics

Revenue (TTM) (Mil) $2,872
EPS (TTM) $ 1.17
Beta0.62
Short Percentage of Float2.26%
52-Week Range $32.64 - 42.97
Shares Outstanding (Mil)279.30

Analyst Estimate

Sep17 Sep18 Sep19
Revenue (Mil $) 2,866 2,993 3,192
EPS ($) 1.97 2.12 2.32
EPS without NRI ($) 1.97 2.12 2.32
EPS Growth Rate
(Future 3Y To 5Y Estimate)
8.19%
Dividends per Share ($)
» More Articles for HOLX

Headlines

Articles On GuruFocus.com
Robert Olstein's Best Performing Investments Include eBay Aug 14 2016 
Carl Icahn's Stakes with Positive Return Aug 04 2016 
Edward Owens Top 2nd Quarter Investments Aug 03 2016 
Carl Icahn's Largest Trades of the 2nd Quarter Jul 19 2016 
Carl Icahn Continues to Reduce Position in Hologic Apr 07 2016 
Investment Ideas Trading With Very Low P/S Ratio Jan 13 2016 
Carl Icahn Makes Big Transactions in 3rd Quarter Jan 03 2016 
Kahn Brothers' Largest Sales During 3rd Quarter Dec 22 2015 
The Best-Performing Stocks Among Vanguard Health Care Fund's Holdings Nov 04 2015 
Amazon Among Ken Fisher's Best Performing Stocks Oct 19 2015 

More From Other Websites
HOLOGIC INC Files SEC form 8-K, Change in Directors or Principal Officers Mar 28 2017
Can Anyone Challenge Allergan In Medical-Aesthetics Market? Mar 24 2017
HOLOGIC INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Other Events,... Mar 23 2017
Hologic Completes Cynosure Buyout, Boosts Core Business Mar 23 2017
Penn National Gaming Set to Join S&P SmallCap 600 Mar 22 2017
Hologic Completes Acquisition of Cynosure Mar 22 2017
Adoption Of 3D Mammography Appears To Be On The Cusp Of An Inflection Mar 13 2017
HOLOGIC INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year,... Mar 09 2017
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Cynosure, Inc. - CYNO Feb 28 2017
Hologic, Inc. breached its 50 day moving average in a Bullish Manner : HOLX-US : February 21, 2017 Feb 21 2017
FDA Grants PMA Approval for Hologic's Aptima® Hepatitis C Quant Dx Assay Feb 15 2017
Hologic to Acquire Cynosure for $1.65 Billion Feb 15 2017
Cynosure (CYNO) to be Acquired by Hologic in $1.65B Deal Feb 15 2017
Hologic downgraded by BofA/Merrill Feb 15 2017
HOLOGIC INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial... Feb 14 2017
Hologic Follows Allergan, Buying Body-Sculptor Cynosure For $1.65 Bil Feb 14 2017
Hologic to buy Cynosure to expand into medical aesthetics Feb 14 2017
Hologic will snap up Westford-based Cynosure in $1.65B deal Feb 14 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)